Product Description
Mechanisms of Action: NOGO Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis
Phase 1: Multiple Sclerosis|Amyotrophic Lateral Sclerosis|Multiple Sclerosis, Relapsing-Remitting
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Breast Cancer |
2019-12-31 |
|||
| JapicCTI-132047 | N/A |
Completed |
Amyotrophic Lateral Sclerosis |
None |
|||
| NCT01435993 | P1 |
Terminated |
Multiple Sclerosis, Relapsing-Remitting |
2012-01-23 |
2019-03-19 |
Treatments |
|
| NCT00875446 | P1 |
Completed |
Amyotrophic Lateral Sclerosis |
2011-09-09 |
2019-03-18 |
Treatments |
|
| NCT01424423 | P1 |
Terminated |
Multiple Sclerosis |
2010-08-26 |
2019-03-19 |
Treatments |
|
| Ozanezumab Phase II study in patients with ALS | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2015-06-06 |
2022-03-13 |
Treatments |
|
| NCT01753076 | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2015-01-22 |
2019-03-22 |
Treatments |